Repetitive Lipid Intake and Food Intake
キーワード
概要
説明
Direct infusion of lipids into different parts of the human small intestine has demonstrated to decrease food intake and subjective appetite feelings, to increase production of the satiety hormones glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and cholecystokinin (CCK), and diminishes gastrointestinal (GI) motility. Amongst oils with different degree of fatty acid saturation, safflower oil (high in linoleic acid, C18:2) was found the strongest inducer of the ileal brake. When ingested orally, however, the major part of dietary lipids will be digested and absorbed in the proximal small intestine and are not likely to induce the ileal brake mechanism. Incorporating small lipid droplets into millimeter-sized calcium (Ca)-alginate gel particles has shown promising results for ileal brake activation. Oral intake of these lipid containing gels have proven to reduce food intake in humans without inducing gastrointestinal symptoms. Contrastingly, to date little is known about repetitive activation of mechanisms of satiety and the effect on food intake. It is not known whether repetitive ileal brake activation provides a stronger brake or whether this will lead to a blunted response and adaptation.
日付
| 最終確認済み: | 01/31/2020 |
| 最初に提出された: | 04/01/2019 |
| 提出された推定登録数: | 04/01/2019 |
| 最初の投稿: | 04/02/2019 |
| 最終更新が送信されました: | 02/20/2020 |
| 最終更新日: | 02/23/2020 |
| 実際の研究開始日: | 10/20/2019 |
| 一次完了予定日: | 09/30/2020 |
| 研究完了予定日: | 09/30/2020 |
状態または病気
介入/治療
Dietary Supplement: Active yogurt
Dietary Supplement: Control yogurt
段階
アームグループ
| 腕 | 介入/治療 |
|---|---|
| Experimental: Active yogurt Contains 120 g yogurt + 60 g oil-gel particles (containing 6 g oil) + 24 g water | Dietary Supplement: Active yogurt Free fat yogurt containing oil-filled alginate gels |
| Active Comparator: Control yogurt Contains 120 g yogurt + 54 g empty gel particles + 6 g oil in 24 g water | Dietary Supplement: Control yogurt Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels |
適格基準
| 研究の対象となる年齢 | 18 Years に 18 Years |
| 研究に適格な性別 | All |
| 健康なボランティアを受け入れる | はい |
| 基準 | Inclusion Criteria: - Based on medical history and previous examination, no serious gastrointestinal complaints can be defined; - Age between 18 and 65 years. This study will include healthy adult subjects (male and female); - BMI between 25-30 kg/m2; - Able to participate in the study, willing to give informed consent and to comply with the study procedures and restrictions; - Weight stable over at least the last 6 months (self-admitted; ≤5% weight change). Exclusion Criteria: - Self-admitted milk (-protein or lactose)- allergy/intolerance; - Self-admitted history of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, haematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided and documented by the principal investigator; - Use of medication that can influence study end-points (to be decided by medical doctor and principal investigator), including vitamin supplementation, within 14 days prior to testing; - Administration of investigational drugs or participation in any scientific intervention study that may interfere with this study, to be decided by the principal investigator prior to the study; - Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery) upon judgement of the principal investigator; - Dieting (medically prescribed, diabetic and vegetarian); - Pregnancy, lactation (both self-admitted); - Excessive alcohol consumption (>20 alcoholic units per week); - Smoking; - Self-admitted HIV-positive state. |
結果
主な結果の測定
1. Repetitive effect on ad libitum food intake [4 days]
二次的な結果の測定
1. Acute effect on ad libitum food intake [3 and 6 hours]
2. Acute vs repetitive on ad libitum food intake [1 day and 4 days]
3. Food intake in normal living setting [2 and 3 days]
4. Feelings of satiety and GI symptoms (VAS scores) [1 day and 4 days]
5. Energy intake compensation [1 day and 4 days]
